Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan
| Autor: | Keiichi Akizuki, Seiichi Sato, Yuki Tahira, Kotaro Shide, Hitoshi Matsuoka, Yoko Kubuki, Noriaki Kawano, Ayako Kamiunten, Junzo Ishizaki, Masaaki Sekine, Kouichi Maeda, Kazuya Shimoda, Tomonori Hidaka, Hiroshi Kawano, Takuro Kameda, Haruko Shimoda, Kiyoshi Yamashita, Masanori Takeuchi, Takanori Toyama |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Multivariate analysis lcsh:Medicine Disease Article 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Internal medicine medicine Multiple myeloma Lenalidomide Bortezomib business.industry lcsh:R prognostic factors General Medicine medicine.disease real-world outcomes international staging system Thalidomide Clinical trial multiple myeloma 030220 oncology & carcinogenesis business 030215 immunology medicine.drug |
| Zdroj: | Journal of Clinical Medicine, Vol 10, Iss 105, p 105 (2021) Journal of Clinical Medicine Volume 10 Issue 1 |
| ISSN: | 2077-0383 |
| Popis: | The prognosis of multiple myeloma (MM) has improved with the introduction of novel agents. These data are largely derived from clinical trials and might not reflect real-world patient outcomes accurately. We surveyed real-world data from 284 patients newly diagnosed with MM between 2010 and 2018 in Miyazaki Prefecture. The median follow-up period was 32.8 months. The median age at diagnosis was 71 years, with 68% of patients aged > 65 years. The International Staging System (ISS) stage at diagnosis was I in 18.4% of patients, II in 34.1%, and III in 47.5%. Bortezomib-containing regimens were preferred as initial treatment they were used in 147 patients (51.8%). In total, 80% of patients were treated with one or more novel agents (thalidomide, lenalidomide, or bortezomib). Among 228 patients who were treated with novel agents as an initial treatment, the overall response rate (partial response (PR) or better) to initial treatment was 78.4%, and the median time to next treatment (TTNT) was 11.6 months. In the multivariate analysis, PR or better responses to initial treatment were independently favorable prognostic factors for TTNT. The median survival time after initial therapy for patients with novel agents was 56.4 months and 3-year overall survival (OS) was 70.4%. In multivariate analysis, ISS stage I/II disease and PR or better response to initial treatment, and autologous stem cell transplantation (ASCT) were identified as independent prognostic factors for overall survival (OS). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|